Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Ointment For Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline~* At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)~* If received certain treatments, should be off treatment for a minimum period of time (washout)~Exclusion Criteria:~* Currently have non-plaque forms of psoriasis or drug-induced psoriasis~* Require treatment with or cannot stop medication(s) prohibited during the study~* Have certain laboratory abnormalities at Baseline~* Current or history of certain infections~* Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: EXPERIMENTAL): None
- Treatment Group B (Type: EXPERIMENTAL): None
- Treatment Group C (Type: PLACEBO_COMPARATOR): None
- Treatment Group D (Type: EXPERIMENTAL): None
- Treatment Group E (Type: EXPERIMENTAL): None
- Treatment Group F (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).